International Biotechnology Center (IBC) Generium, a private scientific research company in Russia that develops medical products and cell-based technologies, has selected Goodwin Biotechnology, a biological contract development and manufacturing organization (CDMO) that specializes in bioprocess development and cGMP manufacturing of biopharmaceuticals utilizing mammalian cell culture expression systems and bioconjugation technologies, for the assay and process technology transfer, process scale-up, and cGMP manufacturing of an IgG-based, bispecific antibody to support early stage clinical trials.

“Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological diseases, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and different kinds of non-Hodgkin’s lymphoma (NHL), and we were looking to partner with a contact manufacturing organization (CMO) to help us optimize the process and manufacture material to be used in Phase I clinical trials,” said Daniil Talyanskiy, chief business officer, IBC Generium.

“Our highly skilled scientists take great pride in working with our clients to enhance the value of their product candidates,” said SooYoung Lee, chief operating officer, Goodwin Biotechnology. “We are excited to be working on IBC Generium’s cutting edge bispecific antibody, bringing to bear our multiple decades of experience in this field.”